



## Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort

Ora Paltiel, Yehiel Friedlander, Efrat Tiram, Micha Barchana, Xiaonan Xue and Susan Harlap

*BMJ* 2004;328;919; originally published online 5 Mar 2004;  
doi:10.1136/bmj.38032.820451.7C

---

Updated information and services can be found at:  
<http://bmj.com/cgi/content/full/328/7445/919>

---

*These include:*

### References

This article cites 22 articles, 6 of which can be accessed free at:  
<http://bmj.com/cgi/content/full/328/7445/919#BIBL>

6 online articles that cite this article can be accessed at:  
<http://bmj.com/cgi/content/full/328/7445/919#otherarticles>

### Rapid responses

3 rapid responses have been posted to this article, which you can access for free at:  
<http://bmj.com/cgi/content/full/328/7445/919#responses>

You can respond to this article at:  
<http://bmj.com/cgi/eletter-submit/328/7445/919>

### Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

---

### Notes

---

To order reprints follow the "Request Permissions" link in the navigation box

To subscribe to *BMJ* go to:  
<http://resources.bmj.com/bmj/subscribers>

# Papers

## Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort

Ora Paltiel, Yehiel Friedlander, Efrat Tiram, Micha Barchana, Xiaonan Xue, Susan Harlap

### Abstract

**Objective** To compare the incidence of cancer among women with and without a history of pre-eclampsia.

**Design** Cohort study.

**Setting** Jerusalem perinatal study of women who delivered in three large hospitals in West Jerusalem during 1964-76.

**Participants** 37 033 women.

**Main outcome measures** Age adjusted and multivariable adjusted hazard ratios for cancer incidence for the entire cohort and for women who were primiparous at study entry.

**Results** Cancer developed in 91 women who had pre-eclampsia and 2204 who did not (hazard ratio 1.27, 95% confidence interval 1.03 to 1.57). The risk of site specific cancers was increased, particularly of the stomach, ovary epithelium, breast, and lung or larynx. The incidence of cancer of the stomach, breast, ovary, kidney, and lung or larynx was increased in primiparous women at study entry who had a history pre-eclampsia.

**Conclusions** A history of pre-eclampsia is associated with increases in overall risk of cancer and incidence at several sites. This may be explained by environmental and genetic factors common to the development of pre-eclampsia and cancer in this population.

### Introduction

Pre-eclampsia, a common complication of pregnancy, is an important cause of short term morbidity and mortality in fetuses and mothers. Risk factors for this condition include nulliparity, previous hypertension, and high maternal weight.<sup>1</sup> Pre-eclampsia has been associated with increased long term mortality for mothers, mainly from cardiovascular causes.<sup>2</sup>

The risk of cancer and risk of death from cancer have been inconsistently associated with pre-eclampsia (see table 1). A cohort study based on the Norwegian birth registry showed a relative hazard of 0.36 for cancer specific mortality among mothers who had had pre-eclampsia between the 16th and 36th week of pregnancy, but the 95% confidence interval was wide (0.12 to 1.11).<sup>2</sup> Another cohort study, based on the Swedish cancer registry, showed no association between pre-eclampsia and cancer of the cervix, endometrium, ovary, or breast.<sup>3</sup> A recent cohort study comparing women with and without a history of pre-eclampsia showed a non-significantly decreased rate ratio for breast cancer; however, pregnancy associated hypertension and specific placental abnormalities were significantly and independently associated with a decreased risk.<sup>4</sup> Furthermore, a large cohort study comparing women with pre-eclampsia or hypertension in their first pregnancy compared with those with-

out showed a significant reduction in risk of breast cancer (rate ratio 0.81, 95% confidence interval 0.71 to 0.91).<sup>5</sup> Three case-control studies found a protective effect of pre-eclampsia on breast cancer with odds ratios ranging from 0.27 to 0.81; one of these, however, was based on only two cases of cancer among women with pre-eclampsia.<sup>6-8</sup> Another was based on a history of hypertension late in pregnancy rather than pre-eclampsia in itself.<sup>7</sup> Several studies have found that maternal pre-eclampsia reduces the risk of breast cancer up to fourfold in female offspring.<sup>9</sup> We investigated overall cancer incidence as well as incidence at specific sites in women in the Jerusalem perinatal study cohort.

### Methods

The Jerusalem perinatal study cohort (92 408 offspring of 44 067 mothers) comprises all births in 1964-76 to residents of West Jerusalem. It was originally planned as a survey of pre-eclampsia, the condition being defined then as a systolic blood pressure of  $\geq 140$  mm Hg or a diastolic blood pressure or  $\geq 90$  mm Hg, or both, together with a proteinuria and oedema. (The currently accepted definition of pre-eclampsia does not include oedema<sup>10</sup>). Baseline data were recorded by the study staff at the time of birth.<sup>11</sup> In 2000 we traced 40 455 (91.8%) of the mothers through the Israel population registry using the unique identity number assigned to all Israeli residents. The 8.2% who remained untraced included a high proportion of foreign nationals and temporary residents. We obtained information on vital status for 39 809 (98.4%) of the traced mothers, the remainder (1.6%) being unavailable for follow up because of emigration or assignment of new identity numbers.

Mothers were linked by way of their identity number to the Israel Cancer Registry, which was set up in 1961. Reporting of cases of cancer has been obligatory by law since 1981, but even before this reporting was considered relatively complete.<sup>12</sup> Quality control surveys are undertaken periodically, the last in 1993, indicating that records of breast cancer are 94.2% complete and records of ovarian cancer are 95.8% complete.<sup>13</sup>

### Statistical methods

We compared the distribution of baseline characteristics as well as the risk of cancer in women with pre-eclampsia recorded at any birth in the cohort (1964-76) with those without pre-eclampsia. After studying the data using life table methods, we used bivariate and multivariate Cox proportional hazards models to assess the risk of cancers at all sites and at specific sites. We adjusted for age and for other factors associated with pre-eclampsia and cancers at specific sites. Age at entry to the cohort was introduced into the models as a continuous variable.

## Papers

**Table 1** Review of studies reporting risk of cancer after pre-eclampsia

Study	Country, population	Design	Definition of exposure	Cancer cases with or without pre-eclampsia	Results				
					Cancer mortality	Overall cancer incidence	Breast cancer incidence	Other specific sites	Comments
Polednak 1983 <sup>6</sup>	USA, <45 years old	Case-control	Toxaemia or pre-eclampsia in first pregnancy	2/15	NR	NR	Odds ratio 0.27 (0.08 to 0.63) <sup>†</sup>	NR	
Thompson 1989 <sup>7</sup>	USA, 20-54 years old	Case-control	Hypertension diagnosed before end of most recent term pregnancy	139/196	NR	NR	Odds ratio 0.73 (0.59 to 0.92)*	NR	
Troisi 1998 <sup>8</sup>	USA, 20-44 years old	Case-control	Toxaemia ever; toxaemia in first pregnancy	97/121; 54/66	NR; NR	NR; NR	Odds ratio 0.81 (0.61 to 1.1)*; odds ratio 0.81 (0.56 to 1.2)*	NR; NR	Adjusted for age, site, race, parity, body mass index, menopausal status
Mogren 2001 <sup>9</sup>	Sweden, Swedish cancer registry	Cohort	Pre-eclampsia (ICD-8 and ICD-9)	NR	NR	NR	No association	No association with cervix or endometrial cancer	
Cohn 2001 <sup>4</sup>	USA, white non-Hispanic	Cohort	Pre-eclampsia in first pregnancy; increase in systolic blood pressure between second and third trimester	2/141; NR	NR; NR	NR; NR	Rate ratio 0.6 (0.17 to 2.09)*; rate ratio 0.5 (0.31 to 0.82)*	NR; NR	Highest quartile of blood pressure change compared with no change; adjusted for age, parity, and weight
Irgens 2001 <sup>2</sup>	Norway, Norwegian birth registry	Cohort	Pre-eclampsia at >37 weeks; pre-eclampsia at 16-36 weeks	NR; NR	0.9 (0.29 to 2.78)*; 0.36 (0.12 to 1.11)*	NR; NR	NR; NR	NR; NR	
Vatten 2002 <sup>5</sup>	Norway, Norwegian cancer registry	Cohort	Pre-eclampsia or hypertension in first pregnancy, or both	280/5194	NR	NR	Rate ratio 0.81 (0.71 to 0.91)*	NR	Adjusted for age, calendar period, age at first birth, parity
Current study	Israel, Jerusalem perinatal study	Cohort	Pre-eclampsia in any pregnancy	91/2204	NR	Hazard ratio 1.27 (1.03 to 1.57)*	Hazard ratio 1.38 (1.0 to 1.89)*	Increased hazard ratio for stomach, lung or larynx, and ovarian	All hazard ratios adjusted for age; breast cancer hazard ratio adjusted for parity as well

NR = not reported.

\*95% confidence interval.

†90% confidence interval.

When assessing risk of breast cancer for all mothers, we adjusted for parity and age simultaneously. Age at entry corresponded to age at first birth for the 22 716 primiparous mothers at study entry. Other variables tested were social class (by husband's occupation), years of education, ethnic origin (west Asia (Iraq, Iran, Kurdistan, Yemen, India, Afghanistan, Turkey, Syria, Lebanon), north Africa (mainly Morocco), Europe or the Americas and other Western countries, or Israeli born), immigration, religion, insulin dependent diabetes mellitus, gestational diabetes, birth weight, and birth defects of the offspring. Follow up was from the first observed birth in the cohort to diagnosis of cancer, death, or 30 June 1999. We excluded women whose diagnosis predated entry into the cohort. The analysis was restricted to the 92% of women delivering in the three largest hospitals in West Jerusalem, in which recording of obstetric complications was deemed to be complete. A priori we also studied the subgroup observed from their first birth. For cancers at specific sites, we restricted the analyses to the 17 sites with at least 25 cases. We report hazard ratios, 95% confidence intervals, and two sided P values.

## Results

The analysis included 37 033 women, of whom 99% were Jewish and 99% were married. Pre-eclampsia was recorded in 1070 (2.9%). Table 2 shows the baseline characteristics of women with and without pre-eclampsia. Pre-eclamptic women were older at baseline. Entry to the study cohort was at the first completed pregnancy for 57.8% for women with and 61.5% of women without pre-eclampsia. Ethnicity of west Asian origin was more com-

mon among women with pre-eclampsia (31.4%) than those without (28.6%). Women with pre-eclampsia were more likely to be of lower social class than those without. Fifty six (5.2%) women with pre-eclampsia had gestational diabetes compared with 349 (1.0%) women without. The median length of follow up was 29 years.

In total, 2295 first primary cancers were reported, including 978 (42.6%) of the breast. After pre-eclampsia there was an overall excess of cancer when all sites were combined (age adjusted hazard ratio 1.27, 95% confidence interval 1.03 to 1.57). The risk of breast cancer was significantly increased for pre-eclamptic women after adjusting for age and parity (1.38, 1.0 to 1.89). The risk of cancers of the stomach, ovary epithelium, and lung or larynx were statistically significantly increased after adjustment for age (table 3). Multivariable adjustment did not substantially change the hazard ratios.

In the 22 716 women followed from their first birth there were increases in age adjusted risk of all cancers (1.58, 1.20 to 2.07) and cancers of the stomach (6.45, 2.16 to 19.3), breast (1.75, 1.19 to 2.58), ovary (3.25, 1.15 to 9.19), kidney (4.83, 1.07 to 21.9), and lung or larynx (2.87, 0.67 to 12.3).

We compared the personal characteristics and outcome of cancer in 2766 women who were excluded from the analysis because they did not deliver in the study hospitals. These women were older at their first birth (mean age 27.3 years for excluded women versus 26.2 for included women) and were more likely to be non-Jewish (6.3% *v* 1.0%) or of European origin (47.2% *v* 34.7%). Cancer occurred in 194 (7.1%), of which 88 (45%) had breast cancer compared with 42.6% in the included cohort. Only 10 women in the excluded group had pre-eclampsia recorded,

**Table 2** Distribution of baseline characteristics of women with and without pre-eclampsia

Variable	No (%) without pre-eclampsia (n=35 963)	No (%) with pre-eclampsia (n=1070)
<b>Age (years) at baseline:</b>		
<20	2517 (7.0)	54 (5.1)
20-24	14361 (39.9)	382 (35.7)
25-29	10078 (28.0)	253 (23.6)
30-34	5284 (14.7)	193 (18.0)
35-39	2792 (7.8)	116 (10.8)
≥40	883 (2.5)	70 (6.5)
Unknown	48 (0.13)	2 (0.19)
<b>Parity at baseline:</b>		
1	22098 (61.5)	618 (57.8)
2	4347 (12.1)	101 (9.4)
3	3490 (9.7)	79 (7.4)
4	1950 (5.4)	62 (5.8)
5 or 6	2073 (5.8)	83 (7.8)
7-9	1430 (4.0)	88 (8.2)
≥10	519 (1.4)	36 (3.4)
Unknown	56 (0.16)	3 (0.28)
<b>Gestational diabetes:</b>		
No	35614 (99.0)	1014 (94.8)
Yes	349 (0.97)	56 (5.2)
<b>Birthplace of woman:</b>		
Israel	16651 (46.3)	450 (42.1)
Other	19312 (53.7)	620 (57.9)
<b>Birthplace of woman's father:</b>		
Israel	5322 (14.9)	149 (13.9)
Other west Asia*	10301 (28.6)	336 (31.4)
North Africa	7845 (21.8)	226 (21.1)
Europe, Americas†	12495 (34.7)	359 (33.6)
<b>Years of education:</b>		
0-8	10726 (29.8)	330 (30.8)
9-12	12953 (36.0)	350 (32.7)
≥13	10715 (29.8)	333 (31.1)
Unknown	1569 (4.4)	331 (31.0)
<b>Social class‡:</b>		
1-2 (high)	12875 (35.8)	357 (33.4)
3-4	13972 (38.9)	381 (35.6)
5-6 (low)	9116 (25.4)	332 (31.0)

\*Includes Iraq, Iran, Kurdistan, Afghanistan, Turkey, Syria, Lebanon, Yemen, India.

†Includes Australia, Southern Africa, North and South America, and Europe.

‡Occupation of husband.

whereas 80 (95% confidence interval 63 to 96) would have been expected given the rate in the entire cohort (2.9%). This indicates systematic underascertainment of pre-eclampsia in this group. Had we included these women in the analysis the age adjusted hazards ratios for cancer at all sites and breast cancer after adjustment for age and parity would have been similar (1.26, 1.02 to 1.55 and 1.39, 1.01 to 1.90, respectively) to those recorded, in which the analysis was restricted to women who delivered in the three major hospitals where pre-eclampsia was systematically ascertained.

## Discussion

In contrast to others (see table 1), we found an increased overall incidence of cancer and site specific increases in cancer of the stomach, ovary, and breast after pre-eclampsia, which was especially noticeable in women followed from their first pregnancy. Results for ovarian and breast cancer were not explained by parity, diabetes, ethnic origin, or social variables. Some, but not all, previous studies have found a protective effect of pre-eclampsia on breast cancer. This has been attributed mainly to decreased oestrogen levels, although recent studies have found that progesterone and androgen levels, rather than oestrogen levels, distinguish women with pre-eclampsia from controls.<sup>9 14 15</sup> Previous studies on pre-eclampsia have been carried out mainly in northern European or North American populations, as have the studies reporting a protective effect on risk of breast cancer.<sup>5-8 16</sup>

The longer follow up in our study may have brought to light associations not previously observed.<sup>6 8</sup> Furthermore, our analysis was restricted to those with and without criteria for pre-eclampsia and did not include all hypertensive diseases of pregnancy, which were coded separately in the database of the Jerusalem perinatal study. This contrasts with other studies that combined the two or studied hypertension in pregnancy.<sup>5 7</sup> We minimised the possibility of biases in selection and ascertainment by relying on a population based cohort with near complete follow up. Obstetrical care for residents of Israel was universally accessible and without charge throughout the study period. The possibility of differential reporting of cancer or ascertainment of cancer in the Israel Cancer Registry according

**Table 3** Incidence of invasive cancers by site and pre-eclampsia status (sites with at least 25 cases)

Cancer site	No of cases		Age adjusted hazard ratio (95% CI)	P value
	No pre-eclampsia (n=35 963)	After pre-eclampsia (n=1070)		
Stomach	46	5	3.10 (1.23 to 7.84)	0.017
Colon	140	7	1.46 (0.68 to 3.12)	0.333
Rectum	68	2	0.86 (0.21 to 3.53)	0.839
Pancreas	27	2	2.06 (0.49 to 8.70)	0.326
Lung or larynx	53	5	2.81 (1.12 to 7.05)	0.028
Melanoma	126	5	1.28 (0.52 to 3.14)	0.584
Breast*	938	40	1.38 (1.0 to 1.89)	0.046
Cervix	62	0	—	—
Endometrium	70	1	0.44 (0.06 to 3.18)	0.417
Ovary epithelium	79	6	2.32 (1.01 to 5.34)	0.047
Bladder	24	1	1.20 (0.16 to 8.93)	0.856
Kidney	36	2	1.52 (0.36 to 6.32)	0.568
Brain or nervous system	30	1	0.94 (0.12 to 6.94)	0.954
Thyroid	114	3	0.87 (0.28 to 2.75)	0.818
Hodgkin's disease	24	1	1.41 (0.19 to 10.43)	0.736
Non-Hodgkin's lymphoma	90	3	1.08 (0.34 to 3.41)	0.898
Leukaemias	32	0	—	—
All others	245	7	0.86 (0.40 to 1.82)	0.689
Total	2204	91	1.27 (1.03 to 1.57)	0.024

\*Adjusted for age and parity.

**What is already known on this topic**

Some studies have suggested a protective effect of pre-eclampsia on risk of cancer

Few population based studies have been performed

Most have been conducted among northern European or North American populations

**What this study adds**

Women with a history of pre-eclampsia are at increased risk of cancer, particularly cancers of the stomach, breast, ovary, and lung and larynx

Specific environmental and genetic factors may contribute to the development of both pre-eclampsia and cancer in Middle Eastern populations

to a previous history of pre-eclampsia is unlikely given the Israeli healthcare system. Recall bias cannot have played a part because pre-eclampsia was diagnosed and recorded at the time of delivery.

We adjusted for age and major risk factors for breast and ovarian cancers; however, we cannot rule out residual confounding. It may be difficult to extrapolate our findings to contemporary parturient women since the current definition of pre-eclampsia no longer includes oedema. Other limitations are the lack of data on the cohort before 1964 and after 1976, which would lead to an underestimate of pre-eclampsia in the cohort, especially among primiparous women at study entry. The possibility remains that some results may be chance findings, as the number of cancers at specific sites is small. Further follow up of this cohort will provide increased power to study these associations.

Ashkenazic (European Jewish) populations are at increased risk of particular cancers, such breast and ovarian cancers, due to mutations in BRCA1, BRCA2, BLM FANCC, and other genes involved in DNA repair; but only a third of our cohort originated in Europe.<sup>17 18</sup> Furthermore, genes that code for DNA repair are not known to contribute to pre-eclampsia. Other mutations in genes affecting thrombophilia or hyperhomocysteinaemia or those influencing angiogenesis and trophoblast invasion might be associated with both pre-eclampsia and cancer in our population.<sup>19 20</sup> We could not adjust for smoking history since data on this exposure were missing for about half the cohort. Nevertheless the finding of increased lung and larynx cancer among those with previous pre-eclampsia is intriguing given the purported protective effect of smoking in pre-eclampsia.<sup>1</sup> On the other hand polymorphisms in the human epoxide hydrolase (a detoxifying enzyme) gene have been associated with both lung and larynx cancer as well as pre-eclampsia,<sup>21-23</sup> providing a possible mechanism for this association. Evidence is emerging for differential effects of candidate genes in the pathogenesis of pre-eclampsia among different populations.<sup>24</sup> Alternatively, diet (for example, folate intake), insulin resistance, smoking, or patterns of infection might represent common pathways in the pathogenesis of cancer and pre-eclampsia, and their effects might be expected to differ between populations.

We thank Lisa Deutsch for assistance in the statistical analysis.

Contributors: OP and SH were responsible for the conception and design of the study, analysis of the data, and the writing and revision of the manuscript; they will act as guarantors for the paper. YF participated in the design

and analysis of the study and preparation of the final manuscript. ET and MB participated in data acquisition and preparation of the final manuscript. ET and XX participated in data analysis and approval of the final manuscript. OP, SH, and YF obtained funding.

Funding: This study was funded by the National Institutes of Health (RO1 CA80197).

Competing interests: None declared.

Ethical approval: The study was approved by the institutional review boards in the participating institutions and by Israel's ministries of health and the interior.

- Odegard RA, Vatten LJ, Tore Nielsen S, Salvesen KA, Austgulen R. Risk factors and clinical manifestations of pre-eclampsia. *Br J Obstet Gynaecol* 2000;107:1410-6.
- Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study. *BMJ* 2001;323:1213-6.
- Mogren I, Stenlund H, Högborg U. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. *Acta Oncologica* 2001;40:849-54.
- Cohn BA, Cirillo RM, Christianson RE, van den Berg BJ, Siiteri PK. Placental characteristics and reduced risk of maternal breast cancer. *J Natl Cancer Inst* 2001;93:1133-40.
- Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. *Br J Cancer* 2002;87:971-3.
- Polednak AP, Janerich DT. Characteristics of first pregnancy in relation to early breast cancer. A case-control study. *J Reprod Med* 1983;28:314-8.
- Thompson W, Jacobson H, Negrini B, Janerich D. Hypertension, pregnancy, and risk of breast cancer. *J Natl Cancer Inst* 1989;81:1571-4.
- Troisi R, Weiss H, Hoover RN, Potischman N, Swanson CA, Brogan DR, et al. Pregnancy characteristics and maternal risk of breast cancer. *Epidemiology* 1998;9:641-7.
- Innes KE, Byers TE. Preeclampsia and breast cancer risk. *Epidemiology* 1999;10:722-32.
- Higgins JR, de Swiet M. Blood-pressure measurement and classification in pregnancy. *Lancet* 2001;357:131-5.
- Davies AM, Prywes R, Tzur B, Wesikopf P, Sterk VV. The Jerusalem Perinatal Study. I. Design and organization of a continuing, community-based, record linked survey. *Isr J Med Sci* 1969;5:1095-1106.
- Steinitz R, Parkin DM, Young JL, Bieber CA, Katz L. *Cancer incidence in Jewish migrants to Israel 1961-1981*. Scientific Publication No 98 Lyon: World Health Organization, International Agency for Research on Cancer.
- Israel Center for Disease Control. *Investigation into the completeness of the Israel Cancer Registry. Methods and results*. Publication 230. Israel Center for Disease Control, Oct 2003:31. (In Hebrew.)
- Tamimi R, Lagiou P, Vatten LR, Mucci L, Trichopoulos D, Hellerstein S, et al. Pregnancy hormones, pre-eclampsia, and implications for breast cancer risk in the offspring. *Cancer Epi Biomarkers Prev* 2003;12:647-50.
- Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, et al. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. *Int J Epidemiol* 2003;32:455-60.
- Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. *Lancet* 2001;357:53-6.
- Struwing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. *Nat Genet* 1995;11:198-200.
- Peleg L, Pessio R, Goldman B, Dotan K, Omer M, Friedman E, et al. Bloom syndrome and Fanconi's anemia: rate and ethnic origin of mutation carriers in Israel. *Isr Med Assoc J* 2002;4:95-7.
- Pridjan G, Puschett JB. Preeclampsia. Part 2: experimental and genetic considerations. *Obstet Gynecol Surv* 2002;57:619-40.
- Sherer DM, Abulafia O. Angiogenesis during implantation and placental and early embryonic development. *Placenta* 2001;22:1-13.
- Zusterzeel P, Peters W, Visser W, Hermsen K, Roelofs H, Steegers E. A polymorphism in the gene for microsomal epoxide hydrolase is associated with preeclampsia. *J Med Genet* 2001;38:234-7.
- Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. *Mol Carcinog* 2002;33:99-104.
- Park JY, Schantz SP, Lazarus P. Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. *Oral Oncol* 2003;39:483-90.
- Chikosi AB, Moodley J, Pegoraro RJ, Lanning PA, Rom L. 5,10 methylenetetrahydrofolate reductase polymorphism in black South African women with pre-eclampsia. *Br J Obstet Gynaecol* 1999;106:1219-20.

(Accepted 21 January 2004)

doi 10.1136/bmj.38032.820451.7C

Braun School of Public Health and Community Medicine, Hadassah-Hebrew University, Jerusalem 91120, Israel

Ora Paltiel *senior lecturer*

Yehiel Friedlander *professor*

Efrat Tiram *doctoral candidate*

Israel Cancer Registry, Ministry of Health, Jerusalem 91010, Israel

Micha Barchana *director*

Department of Epidemiology and Population Health, Albert Einstein College of Medicine of Yeshiva University, New York 10461, USA

Xiaonan Xue *statistician*

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York 10032, USA

Susan Harlap *professor*

Correspondence to: O Paltiel [ora@vms.huji.ac.il](mailto:ora@vms.huji.ac.il)